Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

2 Takeaways from today’s Jefferies London HCC (psst, it’s all about Poziotinib).

The big enchilada was that they mentioned they are going to do a basket study for the Exon 20 Insertion mutation across all cancer types after getting input from the FDA. That is HUGE! That means they don’t have to do a trial in each cancer type like in the old days. They’ll be able to treat any cancer that has the Exon 20 Insertion mutation be it Glioblastoma, gastric cancer, breast cancer, etc. Think of it this way, they added to the # of patients they could treat when in the MD Anderson trial, they included, in additions to the original EGFR patients, HER2 mutations. Now they will be able to look at these mutations across various cancers. Instead of exploring the NSCLC solar system you’re going beyond that into something bigger, the cancer galaxy. That increases the number of patients that can be treated, multiples of what we were thinking of weeks ago.

The other is that they will submit a preliminary request for breakthrough therapy for the Exon 20 Insertion mutation in NSCLC this month! That’s getting the ball rolling!

It was nice to see today’s reaction to the share price up 86 cents (4.57%) to 19.66

Rolontis who?